Clinical trials: Cancer, Advanced Solid Tumors
Select Advanced Solid Tumors
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4).
- Trial name
- NCT06402201
- Testing
- CDR404
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 42 people
- Sponsor
- CDR-Life AG
Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00253565
- Testing
- capecitabine, imatinib mesylate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Hurwitz
Cancer, Metastatic Cancer
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
- Conditions
- Cancer, Metastatic Cancer, Locally Advanced, Locally Advanced Solid Tumor
- Trial name
- NCT06416007
- Testing
- Lattice therapy (LRT)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Cincinnati
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NCT03215511
- Testing
- Selitrectinib (BAY2731954)
- Where
- 29 sites in United States, Australia and 8 more
- Volunteers
- 81 people
- Sponsor
- Bayer
Neoplasms, Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to determine a dose for future development and to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy profiles of JNJ-42756493 in Japanese and other Asian patients with advanced or…
- Conditions
- Neoplasms, Lymphoma, Adenocarcinoma, Esophagogastric Junction
- Trial name
- NCT01962532
- Testing
- Part 1: JNJ-42756493, Part 2: JNJ-42756493
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumor
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension.
- Trial name
- NCT05148533
- Testing
- TJ1133 Injection
- Where
- 22 sites in China
- Volunteers
- 7 people
- Sponsor
- TJ Biopharma Co., Ltd.
HER2 Gene Mutation, Advanced Solid Tumors
HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
- Trial name
- RAD202 (NCT06824155)
- Testing
- 177Lu-RAD202
- Where
- 5 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Advanced Solid Tumor Cancers, Medulloblastoma
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT00880308
- Testing
- LDE225
- Where
- 5 sites in United States, Spain and 2 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors
- Trial name
- NCT05951608
- Testing
- AK127 in combination with AK112
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Akeso
Solid Tumors, Metastatic Melanoma
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3)…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT03708328
- Testing
- Lomvastomig
- Where
- 17 sites in United States, Denmark and 4 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only)
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
Precision oncology has led to a growing population of adults with advanced cancer living increasingly longer lives in the face of profound uncertainty about the future, with over half reporting moderate to high fear of cancer…
- Conditions
- Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer
- Trial name
- EASE (NCT07636200)
- Testing
- Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Colorado, Boulder
Solid Tumors
Dexamethasone for Symptom Burden in Advanced Cancer Patients
The goal of this clinical research study is to learn if dexamethasone can help to control symptoms such as fatigue, pain, nausea, weight loss, loss of appetite, sleep problems, and/or depression in patients with advanced cancer.
- Trial name
- NCT00489307
- Testing
- Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- M.D. Anderson Cancer Center
Merkel Cell Carcinoma, Basal Cell Carcinoma
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer.
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Trial name
- ARTACUS (NCT04349436)
- Testing
- RP1, intra-tumoral injection, oncolytic virus
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Replimune, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced solid…
- Trial name
- NCT00003709
- Testing
- carbendazim
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Solid Tumor
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
The study is being conducted to evaluate the safety and tolerability of SHR-4595 for injection in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and…
- Trial name
- NCT07830199
- Testing
- SHR-4595 for Injection
- Where
- 2 sites in China
- Volunteers
- 208 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor, Esophageal Cancer
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with…
- Conditions
- Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers
- Trial name
- NCT06682806
- Testing
- PRT3789, pembrolizumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Prelude Therapeutics Incorporated
Tumor, Solid
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
- Trial name
- EIK1001 (NCT04196530)
- Testing
- BDB001 (EIK1001), Atezolizumab
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eikon Therapeutics
Advanced Solid Tumors
Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors
This is a dose finding, open-label, uncontrolled, dose-escalation trial to determine the Maximum Tolerated Dose (MTD) and the Recommended Dose (RD) of the combination RAD001 (escalating daily dose) and CaelyxTM (fixed dose) to…
- Trial name
- NCT01148628
- Testing
- RAD 001 in combination with Caelyx
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 54 people
- Sponsor
- Southern Europe New Drug Organization
Advanced Solid Tumor, Lymphomas
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011 is a new oral drug designed to inhibit the activity of an enzyme known as CDK4/6. CDK4/6 is involved in the process that allows both normal and cancer cells to divide and multiply.
- Trial name
- NCT01237236
- Testing
- LEE011
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
- Trial name
- NCT00421044
- Testing
- Patupilone/EPO906
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.